Understanding the roles of mammalian sialidases in glycolipid catabolism
Sialidases are widely distributed in nature, from microorganisms to mammals. Mammalian sialidases differ in their tissue distribution, subcellular localization, substrate specificity and pH optimum. To date, several mammalian sial...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2010-17589
ESTUDIOS SOBRE ENFERMEDADES LISOSOMALES: BASES MOLECULARES,...
18K€
Cerrado
SAF2009-11289
INVESTIGACION SOBRE LAS CAUSAS MOLECULARES Y ESTRATEGIAS TER...
48K€
Cerrado
GLYCANLIPO
Selective glycan recognition using molecularly imprinted lip...
195K€
Cerrado
BFU2010-17711
BASES ESTRUCTURALES PARA LA MANIPULACION EN LA SELECTIVIDAD...
36K€
Cerrado
RTI2018-097801-B-I00
UN NUEVO MECANISMO DE SELECCION Y RECICLADO DE PROTEINAS INT...
145K€
Cerrado
PID2020-112830RB-I00
APROXIMACIONES NO CONVENCIONALES PARA ENTENDER Y TRATAR LAS...
478K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Sialidases are widely distributed in nature, from microorganisms to mammals. Mammalian sialidases differ in their tissue distribution, subcellular localization, substrate specificity and pH optimum. To date, several mammalian sialidases have been cloned; a lysosomal form (Neu1), a cytosolic form (Neu2), a plasma membrane-associated form (Neu3) and a lysosomal/mitochondrial form (Neu4). Defining the functional impact of sialidases on complex physiological and cellular processes should uncover the biological significance of sialidase-susceptible sialic acids on glycoproteins and glycolipids. Our goal has been to clarify biological functions of mammalian sialidases. Recently we investigated the role of lysosomal/mitochondrial sialidase Neu4 in glycolipid degradation using mouse model with the combined deficiency of β-hexosaminidase A (HexA) and sialidase Neu4. Our mouse model progressed toward the neuropathological abnormalities of human Tay-Sachs patients. The appearance of epileptic seizures and increased glycolipid storage demonstrated the predicted increased severity of disease indicative of the importance of Neu4 in glycolipid degradation but it is clear from the much milder than expected phenotype that other sialidases such as Neu1 and Neu3 also contribute to catabolism reactions. We now propose to investigate the intralysosomal mechanism by which glycolipids are degraded by sialidase Neu1 using mouse models. Therefore, the main objectives of this proposal are: (1) to generate first Neu1-/- knockout mouse models (2) to generate Neu1-/-HexA-/- (3) to generate Neu1-/-Neu4-/-HexA-/- triple knockout mouse models. If successful, our studies will significantly increase the state of knowledge of sialidase contribution in glycolipid degradation and can suggest new therapeutic approaches for Tay-Sachs disease based on the Neu1 and Neu4-catalyzed metabolic bypath.